ResMed Inc. (NYSE:RMD) is scheduled to post its quarterly earnings results after the market closes on Thursday, October 26th. Analysts expect ResMed to post earnings of $0.66 per share for the quarter.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.02. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The firm had revenue of $556.69 million for the quarter, compared to analyst estimates of $557.68 million. During the same period in the prior year, the firm posted $0.74 earnings per share. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, analysts expect ResMed to post $3.06 EPS for the current fiscal year and $3.40 EPS for the next fiscal year.

Shares of ResMed Inc. (RMD) opened at 78.87 on Thursday. The firm’s 50-day moving average is $77.89 and its 200 day moving average is $74.33. The company has a market capitalization of $11.22 billion, a price-to-earnings ratio of 32.86 and a beta of 0.77. ResMed Inc. has a 52-week low of $56.59 and a 52-week high of $81.87.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th were paid a dividend of $0.35 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This is a boost from ResMed’s previous quarterly dividend of $0.33. This represents a $1.40 annualized dividend and a yield of 1.78%. ResMed’s dividend payout ratio (DPR) is 58.09%.

In related news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $77.49, for a total value of $96,862.50. Following the completion of the sale, the chief financial officer now owns 59,258 shares in the company, valued at approximately $4,591,902.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Pendarvis sold 6,364 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $72.10, for a total value of $458,844.40. Following the completion of the sale, the insider now owns 84,476 shares of the company’s stock, valued at approximately $6,090,719.60. The disclosure for this sale can be found here. Insiders have sold 107,232 shares of company stock valued at $8,109,182 in the last three months. 1.77% of the stock is owned by insiders.

A number of research firms have recently commented on RMD. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research note on Thursday, October 12th. Jefferies Group LLC reiterated a “sell” rating and set a $56.00 target price on shares of ResMed in a research note on Thursday, October 12th. Barclays PLC boosted their price objective on ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a research note on Monday, September 25th. Needham & Company LLC restated a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Finally, Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. ResMed presently has a consensus rating of “Hold” and an average price target of $68.33.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/19/resmed-inc-rmd-to-release-earnings-on-thursday.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.